NCT00096174已完成2 期
Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 69
- 主要终点
- 2-year Progression-free Survival Rate
研究概览
简要总结
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cetuximab may make the tumor cells more sensitive to radiation therapy and chemotherapy. Giving monoclonal antibody therapy together with chemoradiotherapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab and cisplatin together with radiation therapy works in treating patients with locally advanced or regional stage IV head and neck cancer that cannot be removed by surgery.
详细描述
OBJECTIVES:
Primary
- Determine 2-year progression-free survival in patients with unresectable locally advanced or regional stage IV squamous cell or undifferentiated carcinoma of the head and neck treated with cetuximab, cisplatin, and definitive radiotherapy.
Secondary
- Determine response rate and overall survival in patients treated with this regimen.
- Determine the toxic effects of this regimen in these patients.
- Correlate epidermal growth factor receptor (EGFR) expression by immunohistochemistry, EGFR phosphorylation, map kinase, Akt, signal transducer and activator of transcription 3 (STAT3), and other tissue and serum tests with toxicity of this regimen and outcomes in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed squamous cell or undifferentiated carcinoma of the head and neck (excluding nasopharynx, paranasal sinus, and parotid gland)
- •Unresectable locally advanced or regional stage IV disease
- •No evidence of distant metastases
- •Must have demonstrable primary tumor site
- •Measurable disease
- •Unresectable disease
- •Meets the following criteria for unresectable disease by tumor site:
- •Hypopharynx, meeting 1 of the following criteria:
- •Extension across the midline of the posterior pharyngeal wall
- •Any evidence of fixation to the cervical spine
- •Direct subglottic extension (>3cm) into surrounding muscle or skin
- •Oral cavity
- •Lesion precluding functional reconstruction
- •Base of tongue, meeting 1 of the following criteria:
- •Extension into the root of the tongue
- •Patient refuses total glossectomy
- •Tonsillar area, meeting 1 of the following criteria:
- •Extension into pterygoid area as manifested by x-ray or trismus
- •Extension across midline of pharyngeal wall
- •Direct extension into soft tissue of the neck
- •Unilateral neck node metastases fixed to carotid artery, mastoid, base of skull, or cervical spine with any of the above tumors
- •Patients requiring total glossectomy are eligible
- •Age>=18 years
- •ECOG Performance status of 0-1
- •Adequate hematologic, renal, and hepatic function obtained <=4 weeks prior to registration
- •Absolute neutrophil count ≥ 2,000/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Hemoglobin ≥ 9.0 g/dL
- •Alkaline phosphatase ≤ 3 times normal
- •Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) ≤ 3 times normal
- •Bilirubin ≤ 1.5 mg/dL
- •Creatinine ≤ 1.2 mg/dL OR creatinine clearance ≥ 50 mL/min
- •Able to tolerate fluid load
- •At least 14 days since major surgery (including dental extraction) except percutaneous endoscopic gastrostomy (PEG) placement or mediport placement
排除标准
- •Pregnant or nursing
- •Fertile patients do not use effective contraception
- •Patients who refuse surgery but whose tumors are technically resectable OR whose tumors are unresectable for medical reasons are not eligible
- •Disease metastases below the clavicles or elsewhere (M1) or with a postoperative recurrence
- •Prior excisional surgery of head and neck tumor
- •Prior radiotherapy to the head and neck region
- •Prior chemotherapy
- •Prior drugs that target the epidermal growth factor receptor pathway
- •Prior chimerized or murine monoclonal antibody
- •Active systemic infection
- •Known allergy to murine proteins
- •Severe chronic obstructive pulmonary disease requiring ≥ 3 hospitalizations within the past year
- •Myocardial infarction within the past 3 months
- •Uncontrolled congestive heart failure
- •Unstable or uncontrolled angina
- •Clinically apparent jaundice
- •Postoperative recurrence
- •Other malignancy within the past 3 years except resected basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other in situ tumors
研究组 & 干预措施
Cisplatin, C225, Radiation
Experimental
- Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.
- Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.
- Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months.
干预措施: cetuximab C225 (Biological)
Cisplatin, C225, Radiation
Experimental
- Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.
- Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.
- Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months.
干预措施: cisplatin (Drug)
Cisplatin, C225, Radiation
Experimental
- Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.
- Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.
- Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months.
干预措施: radiation therapy (Radiation)
结局指标
主要结局
2-year Progression-free Survival Rate
时间窗: assessed every 3 months for 2 years
Two-year progression-free survival rate was defined as the proportion of patients that were alive progression-free two years after registration into the study. Disease progression was assessed per modified RECIST criteria, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, in either primary or nodal lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of new lesions. Kaplan-Meier estimate of 2-year progression-free survival was calculated in the 60 eligible and treated patients.
次要结局
- 2-year Overall Survival Rate(assessed very 3 months for 2 years)
- Overall Response Rate(assessed after all chemoradiation therapy completed Week 9, then every 3 months on C225 maintenance therapy, and every 3 months for 2 years, every 6 months post-treatment 2 years from study entry)
研究者
相似试验
已完成
2 期
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung CancerLung CancerNCT00081302Radiation Therapy Oncology Group
已完成
2 期
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00086892Gynecologic Oncology Group
已完成
2 期
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck CancerHead and Neck CancerNCT00005814Memorial Sloan Kettering Cancer Center
已完成
2 期
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung CancerLung CancerNCT00103207Eastern Cooperative Oncology Group72
已完成
2 期
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin ChemotherapyHead and Neck CancerNCT00004865Jonsson Comprehensive Cancer Center